The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III (Dukes' C) colon cancer: Initial safety report for the open-label randomized phase III study (JFMC37-0801).
Katsuyuki Kunieda
No relevant relationships to disclose
Sotaro Sadahiro
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose
Chikuma Hamada
No relevant relationships to disclose
Shigetoyo Saji
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose
Toshihiko Sato
No relevant relationships to disclose
Takashi Hirai
No relevant relationships to disclose
Atsuyuki Maeda
No relevant relationships to disclose
Kazuhiro Yoshida
No relevant relationships to disclose
Hiroki Akamatsu
No relevant relationships to disclose
Masayuki Ohue
No relevant relationships to disclose
Naohiro Ohta
No relevant relationships to disclose
Yusuke Kinugasa
No relevant relationships to disclose
Shoichi Fujii
No relevant relationships to disclose
Junichi Hasegawa
No relevant relationships to disclose
Koji Tamagawa
No relevant relationships to disclose
Shigeki Yamaguchi
No relevant relationships to disclose
Naohiro Tomita
No relevant relationships to disclose